Table 1.
Comparison Of Long-Acting Formulations Of Buprenorphine FDA-Approved For Treatment Of Opioid Use Disorder
| Brand name | Probuphine | Sublocade | Brixadi (US) or buvidal (Europe/Australia) |
|---|---|---|---|
| Molecular name | RBP-6000 | CAM2038 | |
| Pharmaceutical | Previously Braeburn, currently Titan | Indivior | Braeburn Pharmaceuticals/Camurus |
| Indicated population | Stable transmucosal buprenorphine dose of 8 mg or less for three months or longer | Initiated transmucosal buprenorphine (8–24 mg) for a minimum of 7 days. | Initiation of treatment in patients not already receiving buprenorphine or switching from transmucosal buprenorphine |
| Route of administration | Subcutaneous implant | Subcutaneous injection | Subcutaneous injection |
| Duration of effect | 6 months | 1 month | 1 week or 1 month |
| Dosage | 320 mg (Four 80 mg implants) |
100 and 300 mg | 8, 16, 24 and 32 mg (weekly) or 64, 96 and 128 mg (monthly) |
| Long-acting technology | Ethylene vinyl acetate (EVA) polymer | 18% (weight/weight) buprenorphine base in the ATRIGEL Delivery System | Prolonged release FluidCrystal injection depot technology |
| Location | Upper arm | Abdomen | Buttock, thigh, stomach (abdomen) or upper arm |
| FDA-approval | 2016 | 2017 | 2018 (tentative) |
| Plasma concentrations (ng/mL) | Cmax 3.23 Ctrough 0.72 |
Cmax 4.88 (100 mg) 10.12 (300 mg) Ctrough 2.48 (100 mg) 5.01 (300 mg) |
Cmax Weekly 4.35–8.23 Monthly 3.81–6.59 Ctrough Weekly 0.26–0.54 Monthly 0.45–0.93 |
| Provider burden | +++ Live training program Procedural competency |
++ Supervised injection Monthly injections |
++ Supervised injection Weekly or monthly injections |
| Special Handling Requirements | Requires implant procedure Need for removal or replacement every 6 months |
Needs Refrigeration Injection only under skin around umbilicus |
No special requirements |